Katherine L. Wisner

Katherine L. Wisner

Auto-generated profile, based on publicly available information

Katherine L. Wisner

Developing Brain Institute, Children’s National Hospital, Washington, DC 20010, USA

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2013 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
KWKatherine L. Wisner
Katherine L. Wisner
DSDorothy K. Y. Sit
Dorothy K. Y. Sit
MMMary C. McShea
Mary C. McShea
DRDavid M. Rizzo
David M. Rizzo
RZRebecca A. Zoretich
Rebecca A. Zoretich
BHBarbara H. Hanusa
Barbara H. Hanusa
With a period prevalence of 21.9% the year after birth,1 depression is a frequent complication of childbearing. However, recognition and treatment rates are even lower in pregnant and postpartum women (14%) than in the general population (26%).2,3 Low treatment rates are juxtaposed against mounting evidence that antenatal and postpartum depression (PPD) increase the risk for multiple adverse outcomes among women and their offspring. Maternal depression interferes with child development and increases the rates of insecure attachment and poor cognitive performance.4-6 Suicide accounts for about 20% of postpartum deaths7 and is the second most common cause of mortality in postpartum women.7

1 January 2014 in Best Practice & Research Clinical Obstetrics & Gynaecology
Verified
Journal Article
Closed access
MOMichael W. O'Hara
Michael W. O'Hara
KWKatherine L. Wisner
Katherine L. Wisner

1 April 2005 in American Journal of Psychiatry
Verified
Journal Article
Closed access
RGRobert N. Golden
Robert N. Golden
BGBradley N. Gaynes
Bradley N. Gaynes
RER. David Ekstrom
R. David Ekstrom
RHRobert M. Hamer
Robert M. Hamer
FJFrederick M. Jacobsen
Frederick M. Jacobsen
CNCharles B. Nemeroff
Charles B. Nemeroff

15 December 2006 in The Journal of Clinical Psychiatry
Verified
Journal Article
Closed access
PDF file
MFMarlene P. Freeman
Marlene P. Freeman
JHJoseph R. Hibbeln
Joseph R. Hibbeln
KWKatherine L. Wisner
Katherine L. Wisner
JDJohn M. Davis
John M. Davis
DMDavid Mischoulon
David Mischoulon
JRJr.
Jr.
To determine if the available data support the use of omega-3 essential fatty acids (EFA) for clinical use in the prevention and/or treatment of psychiatric disorders. The authors of this article were invited participants in the Omega-3 Fatty Acids Subcommittee, assembled by the Committee on Research on Psychiatric Treatments of the American Psychiatric Association (APA). Published literature and data presented at scientific meetings were reviewed. Specific disorders reviewed included major depressive disorder, bipolar disorder, schizophrenia, dementia, borderline personality disorder and impulsivity, and attention-deficit/hyperactivity disorder. Meta-analyses were conducted in major depressive and bipolar disorders and schizophrenia, as sufficient data were available to conduct such analyses in these areas of interest. The subcommittee prepared the manuscript, which was reviewed and approved by the following APA committees: the Committee on Research on Psychiatric Treatments, the Council on Research, and the Joint Reference Committee. The preponderance of epidemiologic and tissue compositional studies supports a protective effect of omega-3 EFA intake, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), in mood disorders. Meta-analyses of randomized controlled trials demonstrate a statistically significant benefit in unipolar and bipolar depression (p = .02). The results were highly heterogeneous, indicating that it is important to examine the characteristics of each individual study to note the differences in design and execution. There is less evidence of benefit in schizophrenia. EPA and DHA appear to have negligible risks and some potential benefit in major depressive disorder and bipolar disorder, but results remain inconclusive in most areas of interest in psychiatry. Treatment recommendations and directions for future research are described. Health benefits of omega-3 EFA may be especially important in patients with psychiatric disorders, due to high prevalence rates of smoking and obesity and the metabolic side effects of some psychotropic medications.

18 July 2002 in New England Journal of Medicine
Verified
Journal Article
Closed access
KWKatherine L. Wisner
Katherine L. Wisner
BPBarbara L. Parry
Barbara L. Parry
CPCatherine M. Piontek
Catherine M. Piontek
A woman visits the doctor for her six-week postpartum evaluation. She reports that she cannot sleep even if her baby sleeps. She cries daily and worries constantly. She does not feel hungry and is not eating regularly. Making decisions is overwhelming. How should she be evaluated and treated?

18 May 2005 in JAMA
Verified
Journal Article
Closed access
PDF file
EMEydie L. Moses-Kolko
Eydie L. Moses-Kolko
DBDebra Bogen
Debra Bogen
JPJames Perel
James Perel
ABAmy Bregar
Amy Bregar
KUKathleen Uhl
Kathleen Uhl
KWKatherine L. Wisner
Katherine L. Wisner
Review from JAMA — Neonatal Signs After Late In Utero Exposure to Serotonin Reuptake Inhibitors — Literature Review and Implications for Clinical Applications — ContextA neonatal behavioral syndrome linked to in utero serotonin reuptake inhibitor (SRI) exposure during the last trimester of pregnancy has been identified. The US Food and Drug Administration (FDA) and drug manufacturers have recently agreed to a class labeling change for SRIs, which include selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs), to include information about potential adverse events in neonates exposed in utero. Integration of data about the neonatal behavioral syndrome into the management of pregnancy in women who take SRIs is a current challenge for physicians.ObjectivesTo review evidence regarding the SRI-related neonatal syndrome and to help clinicians guide their patients in a risk-benefit decision-making process.Data SourcesWe searched MEDLINE (1966–February 2005) and PsycINFO (1974–February 2005). All articles related to neonatal signs after in utero SRI exposure were acquired, as well as unpublished data on this topic from the FDA advisory committee meeting of June 2004. References cited in case reports and studies were reviewed. Foreign-language literature was included and translated to English.Study Selection and Data ExtractionStudies were included if they had clearly identified maternal SRI exposure for a minimum of the final trimester of pregnancy through delivery and assessed neonatal outcomes. We identified 13 case reports describing a total of 18 cases. Nine cohort studies met criteria. When not included in the published article, relative risks and 95% confidence intervals (CIs) were computed from raw data and summary risk ratios and 95% CIs were determined with Mantel-Haenszel estimates.Data SynthesisCompared with early gestational SRI exposure or no exposure, late SRI exposure carries an overall risk ratio of 3.0 (95% CI, 2.0-4.4) for a neonatal behavioral syndrome. The most SRI-related neonatal case reports involved fluoxetine and paroxetine exposures. Neonates primarily display central nervous system, motor, respiratory, and gastrointestinal signs that are usually mild and disappear by 2 weeks of age. Medical management has consisted primarily of supportive care in special care nurseries. A severe syndrome that consists of seizures, dehydration, excessive weight loss, hyperpyrexia, or intubation is rare in term infants (1/313 quantifiable cases). There have been no reported neonatal deaths attributable to neonatal SRI exposure.ConclusionsAvailable evidence indicates that in utero exposure to SRIs during the last trimester through delivery may result in a self-limited neonatal behavioral syndrome that can be managed with supportive care. The risks and benefits of discontinuing an SRI during pregnancy need to be carefully weighed for each individual patient. Development and validation of assessment methods and clinical management strategies are critical to advancing this research.